ALG-000184 + itraconazole

ALG-000184 + itraconazole is a combination of two oral small molecule drugs. **ALG-000184** is a first-in-class small molecule hepatitis B virus (HBV) capsid assembly modulator developed by Aligos Therapeutics, designed to inhibit the assembly of the HBV capsid, thereby disrupting viral replication and reducing levels of viral DNA, RNA, and antigens[1][3][5][9]. **Itraconazole** is a well-established broad-spectrum triazole antifungal agent that inhibits ergosterol synthesis in fungi by targeting the enzyme 14α-demethylase, and is also known for drug-drug interaction studies due to its potent CYP3A4 inhibition. The specific combination “ALG-000184 + itraconazole” is used in clinical pharmacokinetic studies to evaluate how itraconazole (a strong CYP3A4 inhibitor) affects the metabolism, safety, and exposure of ALG-000184, rather than as a therapeutic combination for disease treatment[1][9]. The primary indication under development for ALG-000184 is chronic hepatitis B.